US · guidance
CMS Pub. 100-03, ch. 1, § 110.3
Anti-Inhibitor Coagulant Complex (AICC)
CIM 45-24
Anti-inhibitor coagulant complex, AICC, is a drug used to treat hemophilia in patients with factor VIII
inhibitor antibodies. AICC has been shown to be safe and effective and has Medicare coverage when
furnished to patients with hemophilia A and inhibitor antibodies to factor VIII who have major bleeding
episodes and who fail to respond to other, less expensive therapies.
History
(Rev. 1, 10-03-03)
Provenance
- Source
- cms.gov
- Retrieved
- 2026-08-25
- Edition
- iom-2026-08-25
- Content hash
f7fd067fb5a31c7564ef97282ca8dd84ea9bf35d31e7d4a1c1f80b61972fa4e9
The link goes to the issuing authority’s own document — the one we read to produce this record. Where a source publishes whole titles rather than sections, your browser may need a moment to jump to the provision.
Unofficial copy of government-published law, reproduced from official sources with full provenance. Not an official publication; verify against official sources before relying on it in a filing. Records in the 'guidance' corpus, and only that corpus, are sub-regulatory (interpretive guidelines, survey procedures) and are not binding law. Validity bounds follow each jurisdiction's declared temporalBasis.